Parmax Pharma open offer ₹42.80, board meet Aug 2026

Board meeting set for June-quarter results

Parmax Pharma Limited has scheduled a meeting of its board of directors on Friday, August 14, 2026. The stated agenda is to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026. Such board meetings are closely watched because they are the formal point where quarterly performance is signed off and disclosed to the market. For small and mid-sized listed companies, the timing of results can also coincide with corporate actions and ownership changes. In Parmax Pharma’s case, the board meeting notice comes at a time when the company is also going through a disclosed change in control.

Open offer announced at a fixed price

Parmax Pharma’s shares are set to see an open offer priced at ₹42.80 per share, following what the disclosure describes as a significant share acquisition. The open offer is described as an exit route for existing public shareholders at a fixed price. The identified acquirers are Dhiren Chandulal Shah and Sunil Chinubhai Shah. The event has been described as a change in control at Parmax Pharma, triggered through a Share Purchase Agreement and a proposed preferential issue.

Size of the offer and key financials

As per the details provided, the open offer involves 23,46,250 shares, representing 26% of the expanded capital. The maximum consideration for the offer is ₹10.04 crore, assuming full acceptance. The disclosure also mentions an escrow amount of ₹5.20 crore. Payment mode for the open offer has been stated as cash.

What triggered the open offer

The open offer is linked to an underlying transaction that combines a share purchase from existing promoters and a proposed preferential issue of equity shares and warrants. The disclosure refers to a Share Purchase Agreement dated June 08, 2026, and a proposed preferential issue, together resulting in a change in control. Fedex Securities Private Limited has filed a public announcement for the mandatory open offer for Parmax Pharma Limited, in connection with this change in ownership and management.

Share purchase agreement details with existing promoters

The acquirers and persons acting in concert (PACs) have entered into a Share Purchase Agreement dated June 08, 2026. Under the SPA, they are to acquire 11,52,450 equity shares from existing promoters Alkesh Mahasukhlal Gopani, Vipul Mahasukhlal Gopani, and Pravina Mahasukh Gopani. The disclosed SPA price is ₹35.00 per share. The total consideration under the SPA is ₹4.03 crore.

The disclosure also states that, upon completion of the underlying transaction, the existing promoters will cease to hold any equity shares in the company. They will be declassified from the promoter and promoter group category. The acquirers and PACs will acquire control over the target company and will be identified as the new promoters.

Preferential issue and warrants mentioned in the structure

Alongside the SPA, the transaction structure includes a preferential issue of equity shares and a preferential issue of warrants. The figures cited in the disclosure include ₹8.32 crore for the preferential issue of equity shares and ₹6.27 crore for the preferential issue of warrants. The open offer consideration of ₹10.04 crore is presented as a mandatory step following the change in control.

Shareholding pattern before the control change

The shareholding pattern cited in the disclosure shows promoter holding unchanged at 30.80% in the March 2026 quarter. The same 30.80% promoter holding is also shown for the June 2026 quarter, with retail and other at 69.20%. Mutual funds, foreign institutions (FII), and other domestic institutions are shown at 0% in the cited pattern.

Pradeep Gosalia share disposal disclosed

Separately, the disclosure states that Pradeep Gosalia disposed of 3,00,000 equity shares in Parmax Pharma Ltd, reducing his holding from 8.09% to 0.07%. The transaction was executed via a share purchase agreement on June 18, 2026. Prior to the disposal, he held 3,02,714 shares (8.09% of total voting capital). After selling 3,00,000 shares, the remaining holding stands at 2,714 shares (0.07%). The seller confirmed that he does not belong to the promoter or promoter group of the company.

The company’s equity share capital is stated as unchanged at 37,41,300 shares, with a face value of ₹10 per share.

Key terms at a glance

Market impact: what is confirmed

The disclosures position the open offer as an exit option for public shareholders at a fixed price of ₹42.80 per share. They also confirm that the acquirers have stated they do not intend to delist the equity shares pursuant to the open offer. The transaction is explicitly described as a change in control, implying a shift in promoter designation once the underlying steps are completed. In addition, the statement that the acquirers will maintain the required 25% minimum public shareholding sets an important boundary condition for post-transaction ownership.

Analysis: why the control change matters

A change in control accompanied by a mandatory open offer is a major corporate event because it formally alters who steers governance and strategic decisions. In Parmax Pharma’s case, the disclosure lays out a multi-part structure: acquisition of promoter shares through the SPA and a proposed preferential issuance of equity shares and warrants. The open offer size is stated at 26% of expanded voting capital, which indicates that the open offer is being assessed against the post-issue capital base referenced in the disclosure. Investors typically track such events for clarity on promoter continuity, public float, and the obligations and intentions stated by incoming acquirers.

What to watch next

The next scheduled milestone is the board meeting on August 14, 2026, for approval of the unaudited standalone results for the quarter ended June 30, 2026. Separately, the open offer process will remain in focus as the change in control proceeds through the SPA and proposed preferential issue described in the disclosures. Any subsequent filings around completion and promoter reclassification will be key for shareholders tracking the transition from the outgoing promoter group to the incoming acquirers.